Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Med Genet. Aug 27, 2014; 4(3): 69-76
Published online Aug 27, 2014. doi: 10.5496/wjmg.v4.i3.69
Published online Aug 27, 2014. doi: 10.5496/wjmg.v4.i3.69
Genome engineering using the CRISPR/Cas system
Takuro Horii, Izuho Hatada, Laboratory of Genome Science, Biosignal Genome Resource Center, Institute for Molecular and Cellular Regulation, Gunma University, Gunma 371-8512, Japan
Author contributions: Horii T and Hatada I contributed to this paper.
Supported by The Grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan; the Ministry of Health, Labour and Welfare of Japan; the National Institute of Biomedical Innovation; the Asahi Glass Foundation; the Ichiro Kanehara Foundation; and the Program for Cultivating Global Leaders in Heavy Ion Therapeutics and Engineering
Correspondence to: Izuho Hatada, PhD, Laboratory of Genome Science, Biosignal Genome Resource Center, Institute for Molecular and Cellular Regulation, Gunma University, 3-39-15 Showa-machi, Maebashi, Gunma 371-8512, Japan. hatada@gunma-u.ac.jp
Telephone: +81-27-2208057 Fax: +81-27-2208110
Received: December 28, 2013
Revised: May 13, 2014
Accepted: May 16, 2014
Published online: August 27, 2014
Processing time: 265 Days and 11.4 Hours
Revised: May 13, 2014
Accepted: May 16, 2014
Published online: August 27, 2014
Processing time: 265 Days and 11.4 Hours
Core Tip
Core tip: This review introduces the latest information about the genome manipulation technology of the clustered regularly at interspaced short palindromic repeats (CRISPR)/CRISPR associated (Cas) system to readers. We focus particularly on the application of CRISPR/Cas in mammalian cultured cells and mice. The problems of off-target effects and the prospects for therapeutic applications of CRISPR/Cas in the future are also discussed.